The ABI1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphocyte line, featuring targeted disruption of the ABI1 gene. This loss-of-function model eliminates ABI1 protein expression, providing a robust system to interrogate ABI1-dependent signaling without clonal selection artifacts. The polyclonal format ensures a heterogeneous mixture of knockout genotypes, enabling physiologically relevant studies of gene function in a human T-cell context.
The parental Jurkat cell line is an immortalized T-lymphocyte model initially isolated from a 14-year-old male with acute lymphoblastic leukemia. Widely employed in immunology and cancer biology, Jurkat cells recapitulate key aspects of T-cell receptor signaling, cytokine production, and apoptotic pathways, making them exceptionally suitable for dissecting signal transduction mechanisms and hematological malignancy research.
ABI1 encodes an essential adaptor protein within the WAVE regulatory complex, integrating signals from upstream activators such as ABL tyrosine kinases (ABL1, ABL2), the T-cell receptor, and growth factor receptors. Upon stimulation, ABI1 interacts with NCKAP1 and WASF1/WAVE1 to nucleate WAVE complex assembly, which subsequently activates the ARP2/3 complex to drive branched actin polymerization. This molecular axis is critical for actin cytoskeletal reorganization, lamellipodia formation, and regulation of cell adhesion.
CRISPR-mediated ablation of ABI1 in Jurkat cells disrupts these interactions, impairing ARP2/3-dependent actin filament nucleation. Consequently, actin-dependent processes such as immune synapse formation, integrin-mediated adhesion, and cell migration are compromised, modeling the cytoskeletal defects underlying altered T-cell activation. Given the leukemic origin of Jurkat cells, this model is particularly relevant for studying the contributions of WAVE complex dysregulation to T-cell malignancies, including those driven by ABI1 fusion proteins.
Researchers can utilize these polyclonal knockout cells to investigate T-cell motility in transwell migration assays, assess adhesion to extracellular matrix components, or profile activation markers via flow cytometry. Western blotting for phosphorylated ABL kinases probes upstream signaling, while co-immunoprecipitation resolves WAVE complex integrity. Additionally, this model supports high-throughput drug screening to identify modulators of actin-dependent pathways. For further information, please contact Ascent Research.
